S100B and neoplasm: Another S100 isoform, S100P, has been described as a key factor in the aggressiveness of pancreatic cancer [30] and has recently been reported as a promising target of monoclonal antibody therapy, significantly reducing tumour growth and metastasis in a mouse model [43].